LncRNA ZFAS1 serves as a prognostic biomarker to predict the survival of patients with ovarian cancer
- Shuang Han
- De‑Zhan Li
- Mei‑Fang Xiao
Published online on: October 25, 2019
Copyright: © Han et al.
This is an open access article distributed under the terms of Creative Commons Attribution License.
| PMC Statistics:
Total PDF Downloads:
| PMC Statistics:
Ovarian cancer (OC) is one of the most fatal types of gynecological malignancy. Certain long non‑coding RNAs (lncRNA) have been reported to have crucial roles in cancer progression. Zinc finger nuclear transcription factor, X‑box binding 1‑type containing 1 antisense RNA 1 (ZFAS1) is a novel regulator lncRNA in various cancer types. The expression pattern of most lncRNAs, including ZFAS1, in OC remains to be determined. In the present study, it was demonstrated that ZFAS1 was overexpressed in OC vs. normal cell lines. However, ZFAS1 was downregulated in OC compared with normal samples in the GEPIA dataset. Furthermore, OC samples of higher stages (stage III/IV) had higher levels of ZFAS1 compared with those in early‑stage OC (stage I/II) samples. Of note, higher ZFAS1 expression was associated with shorter overall survival time and disease‑free survival time of OC patients. Protein‑protein interaction networks of proteins co‑expressed with ZFAS1 in OC were constructed. Furthermore, Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis of genes co‑expressed with ZFAS1 indicated that ZFAS1 is associated with translation, mRNA splicing, cell‑cell adhesion, DNA repair, protein sumoylation, positive regulation of GTPase activity and DNA replication. The present study may provide novel clues to validate ZFAS1 as a biomarker in OC.